Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision.

Zamek-Gliszczynski MJ, Chu X, Cook JA, Custodio JM, Galetin A, Giacomini KM, Lee CA, Paine MF, Ray AS, Ware JA, Wittwer MB, Zhang L; International Transporter Consortium.

Clin Pharmacol Ther. 2018 May 15. doi: 10.1002/cpt.1082. [Epub ahead of print]

PMID:
29761830
2.

Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary.

Paine MF, Shen DD, McCune JS.

Drug Metab Dispos. 2018 Jul;46(7):1041-1045. doi: 10.1124/dmd.117.079962. Epub 2018 May 7.

PMID:
29735755
3.

Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach.

Johnson EJ, González-Peréz V, Tian DD, Lin YS, Unadkat JD, Rettie AE, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 Jul;46(7):1046-1052. doi: 10.1124/dmd.118.081273. Epub 2018 May 7.

PMID:
29735752
4.

Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation.

Tian DD, Kellogg JJ, Okut N, Oberlies NH, Cech NB, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 May;46(5):552-560. doi: 10.1124/dmd.117.079491. Epub 2018 Feb 21.

PMID:
29467215
5.

Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies.

Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF.

Clin Transl Sci. 2017 Sep;10(5):380-386. doi: 10.1111/cts.12473. Epub 2017 May 23.

6.

Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (Camellia sinensis) as a Case Study.

Kellogg JJ, Graf TN, Paine MF, McCune JS, Kvalheim OM, Oberlies NH, Cech NB.

J Nat Prod. 2017 May 26;80(5):1457-1466. doi: 10.1021/acs.jnatprod.6b01156. Epub 2017 Apr 28.

7.

Therapeutic disasters that hastened safety testing of new drugs.

Paine MF.

Clin Pharmacol Ther. 2017 Apr;101(4):430-434. doi: 10.1002/cpt.613.

PMID:
28318023
8.

Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice.

Johnson EJ, Won CS, Köck K, Paine MF.

Biopharm Drug Dispos. 2017 Apr;38(3):251-259. doi: 10.1002/bdd.2061. Epub 2017 Feb 14.

9.

Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.

Gufford BT, Barr JT, González-Pérez V, Layton ME, White JR Jr, Oberlies NH, Paine MF.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):701-10. doi: 10.1002/psp4.12047. Epub 2015 Nov 28.

10.

Assessing Natural Product-Drug Interactions: An End-to-End Safety Framework.

Roe AL, Paine MF, Gurley BJ, Brouwer KR, Jordan S, Griffiths JC.

Regul Toxicol Pharmacol. 2016 Apr;76:1-6. doi: 10.1016/j.yrtph.2016.01.004. Epub 2016 Jan 9.

PMID:
26776752
11.

Movember Is Mustache Month.

Paine MF, Smith BP.

Clin Pharmacol Ther. 2015 Dec;98(6):562-4. doi: 10.1002/cpt.262. No abstract available.

PMID:
26768983
12.

Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Gufford BT, Graf TN, Paguigan ND, Oberlies NH, Paine MF.

Drug Metab Dispos. 2015 Nov;43(11):1734-43. doi: 10.1124/dmd.115.066076. Epub 2015 Aug 27.

13.

Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.

Gufford BT, Chen G, Vergara AG, Lazarus P, Oberlies NH, Paine MF.

Drug Metab Dispos. 2015 Sep;43(9):1353-9. doi: 10.1124/dmd.115.065086. Epub 2015 Jun 12.

14.

Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W, Stewart PW, Barritt AS 4th, Brouwer KL.

Clin Pharmacol Ther. 2015 Apr;97(4):419-27. doi: 10.1002/cpt.66. Epub 2015 Mar 15.

15.

Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.

Thuita JK, Wolf KK, Murilla GA, Bridges AS, Boykin DW, Mutuku JN, Liu Q, Jones SK, Gem CO, Ching S, Tidwell RR, Wang MZ, Paine MF, Brun R.

PLoS Negl Trop Dis. 2015 Feb 5;9(2):e0003409. doi: 10.1371/journal.pntd.0003409. eCollection 2015 Feb.

16.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

17.

Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):462-70. doi: 10.1124/jpet.114.220764. Epub 2014 Dec 15.

18.

Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance.

Barr JT, Jones JP, Oberlies NH, Paine MF.

Drug Metab Dispos. 2015 Jan;43(1):34-41. doi: 10.1124/dmd.114.061192. Epub 2014 Oct 17.

19.

Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.

Ainslie GR, Wolf KK, Li Y, Connolly EA, Scarlett YV, Hull JH, Paine MF.

J Pharmacol Exp Ther. 2014 Dec;351(3):576-84. doi: 10.1124/jpet.114.216838. Epub 2014 Sep 24.

20.

Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.

Gufford BT, Chen G, Lazarus P, Graf TN, Oberlies NH, Paine MF.

Drug Metab Dispos. 2014 Oct;42(10):1675-83. doi: 10.1124/dmd.114.059451. Epub 2014 Jul 9.

21.

Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity.

VanderMolen KM, Ainslie GR, Paine MF, Oberlies NH.

J Pharm Biomed Anal. 2014 Sep;98:260-5. doi: 10.1016/j.jpba.2014.05.038. Epub 2014 Jun 2.

22.

Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.

Brantley SJ, Gufford BT, Dua R, Fediuk DJ, Graf TN, Scarlett YV, Frederick KS, Fisher MB, Oberlies NH, Paine MF.

CPT Pharmacometrics Syst Pharmacol. 2014 Mar 26;3:e107. doi: 10.1038/psp.2013.69.

23.

Understanding the transport properties of metabolites: case studies and considerations for drug development.

Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, Galetin A.

Drug Metab Dispos. 2014 Apr;42(4):650-64. doi: 10.1124/dmd.113.055558. Epub 2013 Dec 17. Review.

24.

Herb-drug interactions: challenges and opportunities for improved predictions.

Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF.

Drug Metab Dispos. 2014 Mar;42(3):301-17. doi: 10.1124/dmd.113.055236. Epub 2013 Dec 11.

25.

A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect".

Won CS, Lan T, Vandermolen KM, Dawson PA, Oberlies NH, Widmer WW, Scarlett YV, Paine MF.

J Clin Pharmacol. 2013 Sep;53(9):982-90. doi: 10.1002/jcph.136. Epub 2013 Jul 23.

26.

A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.

Brantley SJ, Graf TN, Oberlies NH, Paine MF.

Drug Metab Dispos. 2013 Sep;41(9):1662-70. doi: 10.1124/dmd.113.052563. Epub 2013 Jun 25.

27.

Rapid Quantitation of Furanocoumarins and Flavonoids in Grapefruit Juice using Ultra-Performance Liquid Chromatography.

Vandermolen KM, Cech NB, Paine MF, Oberlies NH.

Phytochem Anal. 2013 Nov-Dec;24(6):654-60. doi: 10.1002/pca.2449. Epub 2013 Jun 18.

28.

Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis.

Thuita JK, Wolf KK, Murilla GA, Liu Q, Mutuku JN, Chen Y, Bridges AS, Mdachi RE, Ismail MA, Ching S, Boykin DW, Hall JE, Tidwell RR, Paine MF, Brun R, Wang MZ.

PLoS Negl Trop Dis. 2013 Jun 6;7(6):e2230. doi: 10.1371/journal.pntd.0002230. Print 2013.

29.

Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.

Althagafy HS, Graf TN, Sy-Cordero AA, Gufford BT, Paine MF, Wagoner J, Polyak SJ, Croatt MP, Oberlies NH.

Bioorg Med Chem. 2013 Jul 1;21(13):3919-26. doi: 10.1016/j.bmc.2013.04.017. Epub 2013 Apr 16.

30.

Enhanced bioactivity of silybin B methylation products.

Sy-Cordero AA, Graf TN, Runyon SP, Wani MC, Kroll DJ, Agarwal R, Brantley SJ, Paine MF, Polyak SJ, Oberlies NH.

Bioorg Med Chem. 2013 Feb 1;21(3):742-7. doi: 10.1016/j.bmc.2012.11.035. Epub 2012 Dec 5.

31.

Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug.

Generaux CN, Ainslie GR, Bridges AS, Ismail MA, Boykin DW, Tidwell RR, Thakker DR, Paine MF.

Drug Metab Dispos. 2013 Feb;41(2):518-28. doi: 10.1124/dmd.112.048231. Epub 2012 Dec 6.

32.

A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models.

Harrill AH, Desmet KD, Wolf KK, Bridges AS, Eaddy JS, Kurtz CL, Hall JE, Paine MF, Tidwell RR, Watkins PB.

Toxicol Sci. 2012 Dec;130(2):416-26. doi: 10.1093/toxsci/kfs238. Epub 2012 Aug 31.

33.

Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation.

González-Pérez V, Connolly EA, Bridges AS, Wienkers LC, Paine MF.

Drug Metab Dispos. 2012 Nov;40(11):2136-42. doi: 10.1124/dmd.112.047134. Epub 2012 Aug 15.

34.

Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.

Won CS, Oberlies NH, Paine MF.

Pharmacol Ther. 2012 Nov;136(2):186-201. doi: 10.1016/j.pharmthera.2012.08.001. Epub 2012 Aug 4. Review.

35.

Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis.

Thuita JK, Wang MZ, Kagira JM, Denton CL, Paine MF, Mdachi RE, Murilla GA, Ching S, Boykin DW, Tidwell RR, Hall JE, Brun R.

PLoS Negl Trop Dis. 2012;6(7):e1734. doi: 10.1371/journal.pntd.0001734. Epub 2012 Jul 24.

36.

Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.

Yang J, Atkins WM, Isoherranen N, Paine MF, Thummel KE.

Clin Pharmacol Ther. 2012 Mar;91(3):442-9. doi: 10.1038/clpt.2011.178. Epub 2011 Nov 2.

37.

A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.

Yan GZ, Generaux CN, Yoon M, Goldsmith RB, Tidwell RR, Hall JE, Olson CA, Clewell HJ, Brouwer KL, Paine MF.

Drug Metab Dispos. 2012 Jan;40(1):6-17. doi: 10.1124/dmd.111.040063. Epub 2011 Sep 27.

38.

Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models.

Yan GZ, Brouwer KL, Pollack GM, Wang MZ, Tidwell RR, Hall JE, Paine MF.

J Pharmacol Exp Ther. 2011 May;337(2):503-12. doi: 10.1124/jpet.110.177220. Epub 2011 Feb 14.

39.

Influence of dietary substances on intestinal drug metabolism and transport.

Won CS, Oberlies NH, Paine MF.

Curr Drug Metab. 2010 Nov;11(9):778-92. Review.

40.

The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation.

Ngo N, Brantley SJ, Carrizosa DR, Kashuba AD, Dees EC, Kroll DJ, Oberlies NH, Paine MF.

J Exp Pharmacol. 2010 Jul;2010(2):83-91.

41.

Diamidines for human African trypanosomiasis.

Paine MF, Wang MZ, Generaux CN, Boykin DW, Wilson WD, De Koning HP, Olson CA, Pohlig G, Burri C, Brun R, Murilla GA, Thuita JK, Barrett MP, Tidwell RR.

Curr Opin Investig Drugs. 2010 Aug;11(8):876-83. Review.

PMID:
20721830
42.

Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes.

Kim E, Sy-Cordero A, Graf TN, Brantley SJ, Paine MF, Oberlies NH.

Planta Med. 2011 Feb;77(3):265-70. doi: 10.1055/s-0030-1250259. Epub 2010 Aug 17.

43.

Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.

Lee JK, Paine MF, Brouwer KL.

J Pharmacol Exp Ther. 2010 Aug;334(2):410-8. doi: 10.1124/jpet.110.165852. Epub 2010 Apr 29.

44.

Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.

Brantley SJ, Oberlies NH, Kroll DJ, Paine MF.

J Pharmacol Exp Ther. 2010 Mar;332(3):1081-7. doi: 10.1124/jpet.109.161927. Epub 2009 Nov 24.

45.

Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans.

Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC, Oberlies NH, Paine MF.

Drug Metab Dispos. 2009 Mar;37(3):514-22. doi: 10.1124/dmd.108.024968. Epub 2008 Dec 29.

46.

A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes.

Wang MZ, Wu JQ, Dennison JB, Bridges AS, Hall SD, Kornbluth S, Tidwell RR, Smith PC, Voyksner RD, Paine MF, Hall JE.

Proteomics. 2008 Oct;8(20):4186-96. doi: 10.1002/pmic.200800144.

PMID:
18792928
47.

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL.

Drug Metab Dispos. 2008 Aug;36(8):1465-9. doi: 10.1124/dmd.107.020065. Epub 2008 May 19.

48.

Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine.

Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, Watkins PB.

Am J Clin Nutr. 2008 Apr;87(4):863-71.

PMID:
18400708
49.

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.

Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF.

Drug Metab Dispos. 2008 Jan;36(1):146-54. Epub 2007 Oct 22.

50.

Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.

Wang MZ, Wu JQ, Bridges AS, Zeldin DC, Kornbluth S, Tidwell RR, Hall JE, Paine MF.

Drug Metab Dispos. 2007 Nov;35(11):2067-75. Epub 2007 Aug 20.

Supplemental Content

Loading ...
Support Center